Researchers at the Harvard University’s Stem Cell Institute have engineered stem cells to become insulin producing cells, potentially providing an important source of pancreatic cells for the development of more effective treatment alternatives for millions of diabetics around the world. The technique increased insulin-producing cell yield from 30% to 80% by targeting the production of a specific protein utilized by insulin-producing beta cells. This enabled the researchers to concentrate the stem cells and yield more beta cells that can then be transplanted into diabetic individuals. Additionally, the concentration of cells should allow researchers to use smaller and less invasive devices to deliver the therapeutic cells in clinically relevant numbers.
With the number of affected patients from Type I and II diabetes growing each year, this innovative approach to cell regeneration and differentiation has the potential to help countless patients restore normal pancreatic function and avoid reliance on constant blood sugar monitoring and insulin injections.
To learn more about stem cells, and how families can bank their own valuable stem cells, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.